IMRX Immuneering Corporation
Healthcare$5.27-2.23%ClosedMarket Cap: $191.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
737.34
DCF Value
$2.80
FCF Yield
-25.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.1%
ROA
-0.0%
ROIC
-0.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-15.3M | $-13.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-13.8M | $-11.6M | $— | — |
| FY null | $0.00 | -Infinity% | $-59.4M | $-56.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-15.4M | $-15.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-14.8M | $-14.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.5M | $-15.0M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-18.6M | $-18.1M | $— | — |
| FY null | $0.00 | NaN% | $-64.1M | $-61.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-15.3M | $-14.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-14.9M | $-14.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.3M | $-14.3M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-16.3M | $-15.1M | $-0.52 | — |